Perpetual Ltd Has $263,000 Position in Boston Scientific Co. (NYSE:BSX)

Perpetual Ltd decreased its holdings in shares of Boston Scientific Co. (NYSE:BSX) by 14.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,833 shares of the medical equipment provider’s stock after selling 651 shares during the quarter. Perpetual Ltd’s holdings in Boston Scientific were worth $263,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Bruce G. Allen Investments LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $28,000. Frazier Financial Advisors LLC bought a new position in shares of Boston Scientific during the fourth quarter worth approximately $32,000. Sachetta LLC bought a new stake in Boston Scientific in the 4th quarter valued at $32,000. Jones Financial Companies Lllp grew its holdings in Boston Scientific by 53.0% in the 4th quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 193 shares in the last quarter. Finally, Venturi Wealth Management LLC increased its position in Boston Scientific by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 215 shares during the period. 89.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on BSX shares. Argus boosted their target price on shares of Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, May 28th. Barclays boosted their price target on Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Deutsche Bank Aktiengesellschaft lifted their price objective on Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, April 25th. Citigroup increased their target price on Boston Scientific from $85.00 to $87.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Finally, Raymond James raised their price target on Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Three analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $76.70.

Boston Scientific Trading Up 0.9 %

NYSE:BSX opened at $77.71 on Friday. Boston Scientific Co. has a 52 week low of $48.35 and a 52 week high of $77.81. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The firm’s fifty day moving average is $73.90 and its 200-day moving average is $66.75. The firm has a market cap of $114.01 billion, a P/E ratio of 65.30, a P/E/G ratio of 2.63 and a beta of 0.81.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. Equities analysts expect that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $75.33, for a total transaction of $526,029.39. Following the transaction, the executive vice president now directly owns 45,628 shares in the company, valued at approximately $3,437,157.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $75.33, for a total value of $526,029.39. Following the completion of the sale, the executive vice president now directly owns 45,628 shares in the company, valued at approximately $3,437,157.24. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP John Bradley Sorenson sold 16,351 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the transaction, the executive vice president now directly owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. Insiders sold 81,627 shares of company stock valued at $5,937,353 over the last 90 days. Company insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.